1 | ANTI-integrin - vedolizumab IV and SC | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 💬
|
2 | EX-vivo stimulation OF cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab | - | - | - | - | 1件: 97 97 💬
|
3 | Fluorescence molecular imaging procedure using vedolizumab-800CW with prior administration OF unlabeled vedolizumab | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬
|
4 | Fluorescence molecular imaging procedure without prior administration OF vedolizumab-800CW | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬
|
5 | Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬
| 1件: TNF TNF 💬
| 66件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 96 96, 97 💬
|
6 | Infliximab, adalimumab, golimumab, vedolizumab, ustekinumab | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬
| 1件: TNF TNF 💬
| 66件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬
|
7 | PK-model TO decide when TO dose vedolizumab and ustekinumab | - | - | - | - | 2件: 96 96, 97 💬
|
8 | Vedolizumab | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 3件: 94 94, 96, 97 💬
|
9 | Vedolizumab 108 MG SC | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬
|
10 | Vedolizumab 300 MG | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬
|
11 | Vedolizumab 300 MG IV | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬
|
12 | Vedolizumab injection | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬
|
13 | Vedolizumab intravenous injection | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬
|
14 | Vedolizumab IV | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 3件: 94 94, 96, 97 💬
|
15 | Vedolizumab IV 300 MG | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 96 96 💬
|
16 | Vedolizumab SC | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬
|
17 | Vedolizumab SC 108 MG | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬
|
18 | Vedolizumab subcutaneous injection | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬
|
19 | Vedolizumab, entyvio | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 2件: 96 96, 97 💬
|
20 | Vedolizumab, ustekinumab, or tofacitinib | 1件: Vedolizumab Vedolizumab (Vedolizumab) | 1件: Vedolizumab
Vedolizumab
(Vedolizumab, Vedolizumab, VEDOLIZUMAB) 💬
| 2件: ITGA4 ITGA4, ITGB7 💬
| 16件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Transcriptional misregulation in cancer, Yersinia infection 💬 | 1件: 97 97 💬
|